DEBIRI for colorectal cancer liver metastases treatment {#S0001}
=======================================================

Despite the introduction of new chemotherapeutic agents and the development of locoregional therapies (embolization, percutaneous ablation, hepatic arterial-directed infusion chemotherapy, internal radiation) that have contributed to better outcomes for colorectal cancer liver metastases (CRC-LM) \[[@B1],[@B2]\], there is still a lack of standardized evidence-based protocols for optimal CRC-LM management \[[@B3]\].

Conventional transarterial chembolization (cTACE) with lipiodol has positive results for the treatment of hepatocellular carcinoma (HCC) \[[@B4]\] and for CRC-LM when used in combination therapies. Clinical indications for DEBIRI according to European Society fo Medical Oncology and National Comprehensive Cancer Network \[[@B1]\] are: presence of advanced disease that is not indicated to surgery and/or refractory to systemic therapy, Eastern Cooperative Oncology Group 2, Child-Pugh B, Barcelona Clinic Liver Cancer C, normal hematological values, ALT and GGT \<3 × upper limit of normal levels; total bilirubin \<2.5 mg/m. \[[@B5]\]. This indication is confirmed by several studies and recent reviews \[[@B1],[@B2],[@B7],[@B8]\]. European Society for Medical Oncology

The comparison of hepatic arterial therapies (radioembolization and TACE) in CRC-LM patients shows a similar median overall survival (OS) of 15.2 months \[[@B6]\], suggesting their positive efficacy in these patients. More recently, there has been an increasing use of TACE with irinotecan-loaded drug eluting beads (DEBIRI) in the treatment of CRC-LM \[[@B7]\]. This article reviews the current literature on DEBIRI reporting its use, efficacy in terms of tumor response and survival and side effects.

DEBIRI: mechanism & function {#S0002}
============================

The use of drug eluting beads (DC-Beads) for the intra-arterial delivery of irinotecan was introduced in early 20th century for the treatment of CRC-LM \[[@B10]\]. DEBIRI involves the delivery of DC-Beads inside the hepatic artery of the lobe mainly affected by tumor metastases. TACE is also used in patients with bilobar disease, alternating the lobe in individual treatments. The tumor specificity of DEBIRI is given by the presence of a richer vascularity inside the tumor than in the normal liver tissue \[[@B18]\]. DEBIRI efficacy has been confirmed by several studies showing high percentage of tumor response \[[@B10]\].

DEBIRI selectivity, however, is different from that of TACE with doxorubicin in HCC. This may be due to the different loco regional activity of irinotecan and the necrotic activity of doxorubicin \[[@B19]\]. The irinotecan is rapidly released from DC-Beads inside tumor metastases, reducing significantly the systemic exposure to the drug and increasing its local concentration. DC-Beads, moreover, occlude liver arterial vessels, increasing the selectivity for tumor tissue that is supplied mainly by hepatic arterial circulation. The normal liver tissue, on the contrary, is mainly supplied by the portal vein and is not affected by the ischemia induced by TACE, as shown in animal models \[[@B20]\]. The ischemic effect alone is not enough to justify the extent of tumor response observed but also the irinotecan effect is required. The use of DC-Beads alone, indeed, results in a lower tumor response than that obverted in a dose-dependent manner of DEBIRI, confirming the importance of both embolization and drug activity \[[@B21]\]. Another important result of embolization-induced ischemia is the rapid decrease of liver pH that activate irinotecan \[[@B22]\].

DEBIRI activity & clinical application {#S0003}
======================================

Type & size of the embolics {#S0004}
---------------------------

There are several types of embolics for the irinotecan delivery. Recent improvements of TACE, including the introduction of new types of embolics (PEG microspheres), have increased tumor response in CRC-LM patients \[[@B23],[@B24]\]. Some type of beads (LUMI) incorporate an imaging agent and can be loaded with a chemotherapeutic drug and can be visualized during TACE and in follow-up imaging \[[@B25]\].

The available beads diameters are different and can be selected according to tumor size and vascularization. At first, the DC-Beads of 100--300 μm were the most used \[[@B16]\], later the 70--150 μm DC-Beads M1 were introduced \[[@B28]\] because of the hypo vascularity of CRC-LM. The smaller diameter allowed a more distal penetration of the beads \[[@B29]\], allowing a higher concentration of irinotecan administered inside the tumor and fewer adverse events \[[@B30]\]. A comparison between DEBIRI performed using DC-Beads with small (70--150 μm) versus big (100--300 μm) diameter showed that small beads delivered significantly (p \> 0.005) a higher drug concentration (96%) inside the target than the big beads (79%) and a complete stasis in a lower number of TACE in CRC-LM patients (p \< 0.005) \[[@B31],[@B32]\]. This result was further supported by the pharmacokinetic study of irinotecan release from small and big size DC-Beads that showed an advantage for small size beads as concerning the maximum concentration of irinotecan observed in the target area and low adverse events \[[@B33]\]. This effect may be due to a higher surface area/volume associated with DC-Beads M1. However, the 100--300 μm beads remain the most used size ([Table 1](#T1){ref-type="table"}).

###### DEBIRI support therapy protocols and adverse events in colorectal cancer liver metastases.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (year)                 Patients (n)   Intra-arterial support therapy   Embolic type   Embolic diameter (μm)   Average irinitecan dosage (mg)   Type of adverse event                 Peri-procedural therapy                                                       Ref.
  ---------------------------- -------------- -------------------------------- -------------- ----------------------- -------------------------------- ------------------------------------- ----------------------------------------------------------------------------- ------------
  Fiorentini *et al.* (2017)   50             Lidocaine                        LP             100                     200                              Pain 16 (32%)\                        Intravenous hydration\                                                        \[[@B23]\]
                                                                                                                                                       Fever 7 (14%)\                        10 mg morphine\                                                               
                                                                                                                                                       Hypertransaminasemia 10 (20%)         2 mg ondasentron\                                                             
                                                                                                                                                                                             400 mg Ciprofloxacin\                                                         
                                                                                                                                                                                             Paracetamol in the case of fever                                              

  Ranieri *et al.* (2016)      25             No                               HS             100--300                100--200                         Pain 22%\                             Intravenous hydration\                                                        \[[@B34]\]
                                                                                                                                                       Hypertension 30%\                     Morphine\                                                                     
                                                                                                                                                       Fever 16%\                            Antiemetic and antibiotic prophylaxis\                                        
                                                                                                                                                       Hyper-transaminasemia 69%             Morphine post-procedure                                                       

  Stutz *et al.* (2015)        27             No                               DC             100--300, 300--500      50--200                          Nausea 8 (30%)\                       Antiemetics\                                                                  \[[@B35]\]
                                                                                                                                                       Vomiting 6 (22%)\                     Antibiotics and standards protocol for right upper quadrant pain prevention   
                                                                                                                                                       Right upper quadrant Pain 5(59%)\                                                                                   
                                                                                                                                                       Fatigue 9 (33%)\                                                                                                    
                                                                                                                                                       Ascites 6 (22%)                                                                                                     

  Fiorentini *et al.* (2015)   40             Lidocaine                        DC             100--300, 300--500      200                              PES 20 (30%)\                         Intravenous hydration\                                                        \[[@B36]\]
                                                                                                                                                       Gastritis 6 (15%)\                    10 mg morphine\                                                               
                                                                                                                                                       Dehydration (G2) 2 (5%)\              2 mg ondasentron\                                                             
                                                                                                                                                       Cholecystitis (G3) 1 (2.5%)\          400 mg Ciprofloxacin\                                                         
                                                                                                                                                       Hypertension (G2) 7 (17.5 %)          Paracetamol in case of fever                                                  

  Eichler *et al.* (2012)      25             Lidocaine                        DC             100--300, 300--500      73                               Nausea 8 (30%)\                       Pethidine\                                                                    \[[@B37]\]
                                                                                                                                                       Vomiting 6 (22%)\                     Granisentron                                                                  
                                                                                                                                                       Right upper quadrant Pain 17 (59%)\                                                                                 
                                                                                                                                                       Fatigue 9 (33%)\                                                                                                    
                                                                                                                                                       Ascites 6 (22%)                                                                                                     

  Fiorentini *et al.* (2012)   36             Lidocaine                        DC             100--300, 300--500      200                              Pain 30%\                             Intravenous hydration\                                                        \[[@B16]\]
                                                                                                                                                       Vomiting 25%\                         10 mg morphine\                                                               
                                                                                                                                                       Diarrhea 2%\                          2 mg ondasentron\                                                             
                                                                                                                                                       Asthenia 20%\                         400 mg Ciprofloxacin\                                                         
                                                                                                                                                       Leukopenia 5%\                        Paracetamol in case of fever                                                  
                                                                                                                                                       Anaemia 5%\                                                                                                         
                                                                                                                                                       Fever 15%\                                                                                                          
                                                                                                                                                       Alopecia 5%                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DC: Drug eluting bead (Biocompatibles, Farnham, UK); HS: HepaSphere (BioSphere Medical, Roissy-en-France, France); LP: LifePearl (Terumo, Leuvent, Belgium); ND: Not declared; PES: Postembolic syndrome.

The DC-Beads 40 μm diameter embolic microspheres were recently introduced for DEBIRI, resulting in small toxicity and good efficacy: local tumor control of 88.9%, median liver progression-free survival (PFS) of 5.9 months and median OS of 13.5 months \[[@B38]\].

DC-Beads are loaded with irinotecan. Irinotecan molecule terminates in an open-ring carboxylate that is converted to a closed-ring lactone (active form) in a pH-dependent manner \[[@B21]\]. This latter form binds better to the sulfonate groups that are present in the DC-Beads \[[@B21]\]. Irinotecan is loaded to the beads in a prodrug form and is activated by carboxylesterase that are present in several parts of the body, such as gut, liver and blood \[[@B21]\]. The activated drug can bind to its target (TOPO-1) 1000-times stronger than the inactive form and interferes with DNA replication, resulting in single strand breaks in DNA and hence, apoptosis of the tumor cell \[[@B21]\].

DEBIRI-related side effects {#S0005}
---------------------------

Due to the local delivery of irinotecan, DEBIRI does not induce dose-dependent side effects (neutropenia and diarrhoea) that are generally observed as a consequence of the systemic administration \[[@B13]\]. The adverse events commonly observed after TACE are fever without associated sepsis, pain in the right upper quadrant, pain due to capsular starching associated with postinterventional reaction and swelling, nausea and/or vomiting ([Table 1](#T1){ref-type="table"}) \[[@B39]\]. These symptoms are referred to as postembolization syndrome. Right upper quadrant pain is the most discomforting adverse event, in particular during the beads injection. Incidence of adverse events correlated to DEBIRI varies between different studies, median incidence is 57% for nonserious adverse event and 11% for serious adverse events ([Tables 2](#T2){ref-type="table"} & [3](#T3){ref-type="table"}).

###### DEBIRI results in prospective single arm studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                       Aims               Prior CHT   Patients (n)   OS                   PFS              AE                    SAE                  Ref.
  --------------------------- ------------------ ----------- -------------- -------------------- ---------------- --------------------- -------------------- ------------
  Aliberti *et al.* (2011)    Safety             Yes         82             25 months            TTP 8 months     N/A                   25%                  \[[@B40]\]

  Martin *et al.* (2011)      Safety efficacy    Yes         55             19 months            11 months        28 in 99 sessions     7 in 99 sessions     \[[@B41]\]

  Eichler *et al.* (2012)     Safety             Yes         11             N/A                  TTP 5.1 months   43 in 9 sessions      None                 \[[@B37]\]

  Martin *et al.* (2012)      Safety             No          10             N/A                  N/A              99 in 10 PTS          4 in 40 PTS          \[[@B42]\]

  Iezzi *et al.* (2015)       Safety efficacy    Yes         20             7.3 months           4 months         64 in 54 sessions     2 in 54 sessions     \[[@B43]\]

  Pellerin *et al.* (2019)    Efficacy           No          57             33 months            10.8 months      G2\                   G3--4\               \[[@B44]\]
                                                                                                                  10--25%               5--9%                

  Martin *et al.* (2015)      Safety efficacy    Yes         30             N/A                  N/A              19 in 57 sessions     3 in 57 sessions     \[[@B42]\]

  Bhutiani *et al.* (2016)    Safety efficacy    Yes         296            88% at 12 months     N/A              105 in 666 sessions   30 in 666 sessions   \[[@B45]\]

  Akinwande *et al.* (2016)   Safety efficacy\   Yes         15             13 months            N/A              2 in 32 sessions      None                 \[[@B32]\]
                              70--150 μm                                                                                                                     

  Scevola *et al.* (2017)     Safety efficacy    Yes         62             27,5% at 51 months   N/A              79 in 174 sessions    None                 \[[@B46]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

AE: Adverse event; CHT: Chemotherapy; G: Grade; IRI: Irinotecan; N/A: Not applicable; OS: Overall survival; PFS: Progression-free survival; PTS: Patient; SAE: Serious adverse event; TTP: Time to progression.

###### DEBIRI results in randomized controlled studies.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                        Aims                                        Prior CHT   Patients (n)   OS                                PFS                AE G1--2     SAE G3--4   Ref.
  ---------------------------- ------------------------------------------- ----------- -------------- --------------------------------- ------------------ ------------ ----------- ------------
  Fiorentini *et al.* (2012)   DEBIRI vs FOLFIRI                           Yes         74             22 vs 15 months\                  7 vs 4 months\     14 vs 18%    2 vs 4%     \[[@B16]\]
                                                                                                      (p = 0.031)                       (p = 0.006)                                 

  Martin *et al.* (2015)       FOLFOX+/− Beva + DEBIRI vs FOLFOX+/− Beva   No          70             Not reached at publication time   15 vs 12 months\   973 vs 459   57 vs 15    \[[@B42]\]
                                                                                                                                        (p \> 0.05)                                 

  Fiorentini *et al.* (2019)   DEBIRI vs DEBIRI + BEVA                     Yes         30             5.8 vs 12 months                  4 vs 6 months      12 vs 16     None        \[[@B47]\]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AE: Adverse event; BEVA: Bevacizumab; CHT: Chemotherapy; G: Grade; OS: Overall survival; PFS: Progression-free survival; SAE: Serious adverse event.

There are different opinions concerning the origin of this type of pain. At first it was deemed the irinotecan responsible for pain, however, the systemic infusion of irinotecan does not cause pain \[[@B12]\]. Another hypothesis is that the swelling induced by the osmotic alteration correlated to the loading solution of the beads, however, intrahepatic infusion of irinotecan at high concentration does not cause pain \[[@B10],[@B14]\].

In some cases, the origin of pain may be due to the mislocalization of the beads that are not delivered inside the target but reach extra target tissues such as the cholecystis as the result of patients' arterial vessel anomalies \[[@B39]\]. The introduction of radiopaque DC Beads LUMI™ allows to rapidly detect the mislocalization and to prevent the correlated adverse event.

Notwithstanding the unclear origin of pain, it can be prevented with supportive therapy with morphine and intra-arterial lidocaine that are administered before the TACE, and antibiotic/antiemetic prophylaxis and intravenous hydration before and after the procedure \[[@B39]\].

In the past decade, several efforts have been made to improve TACE tolerability, including drug dosage adjustments, incremental experience of interventional radiologist, introduction of new type of drugs and microspheres to obtain a more precise and selective treatment \[[@B23]\].

Support therapy protocol for DEBIRI {#S0006}
-----------------------------------

From 2006, Fiorentini and colleagues developed a pre- and post-procedural supportive therapy to prevent and limit acute toxic effects correlated to the DEBIRI procedure. This protocol includes a careful therapy with morphine and intra-arterial lidocaine that are administered before the DEBIRI, and antibiotic/antiemetic prophylaxis and intravenous hydration before and after the procedure. This protocol allows a tolerability of 90% \[[@B13],[@B23],[@B24]\] The cardiac evaluation with echocardiography did not reveal any significant variation before and after last TACE \[[@B23],[@B24]\]. Hence DEBIRI could be considered safe as concerning the cardiac profile, unless in presence of concomitant heart disease.

The analysis of the literature shows that only few studies detail the protocol of supportive therapy for patients that undergo TACE \[[@B34],[@B48]\]. Ranieri and colleagues, for example, administer intravenous hydration, antiemetic and antibiotic prophylaxis, and morphine to reduce post embolic syndrome. Morphine is also administered in the postprocedure period \[[@B34]\].

All patients were treated according to hospital procedure for TACE; routine prophylactic treatments against nausea and vomiting, infection and upper right quadrant pain were also given to patients prior to the procedure. These included antiemetic medications as well as antibiotics and were given prior to TACE procedures ([Table 3](#T3){ref-type="table"}) \[[@B35]\].

General recommendations to avoid pain are: to explain the procedure very well to the patient and their family; to create a welcoming and calm environment in the IR room; to adopt periprocedural medications and lidocaine IA; to perform Lobar Infusion, to avoid the complete flow block; to perform a slow infusion for 1 min for 1 ml of solution; to shake the syringe to keep the beads in suspension; to stop and restart the TACE if pain appears, without hurry; not to perform control angiogram because this causes beads to move out of the target; to carefully monitor the patient after TACE.

Radiological assessment & tumor response evaluation after DEBIRI in CRC-LM {#S0007}
--------------------------------------------------------------------------

The radiological study of CRC-LM is required for the assessment of tumor response and can be done using MRI, computed tomography (CT) and positron emission tomography (PET) scan \[[@B51]\]. Specificity for the detection of liver metastases of CT, MRI and PET is very high: 95, 93, 97%, respectively \[[@B52]\]. CT scans, however, are not always adequate as radiological tool to assess tumor response of DEBIRI \[[@B53]\]. MRI with liver-specific contrast agents has a higher sensitivity, especially when underlying liver diseases (steatosis, cirrhosis) are present or for the identification of very small lesions (\<1 cm), and for this reason it is better than CT \[[@B54]\]. PET scan allows to obtain whole body map and a recent study shows that it is the best radiological method for the assessment of liver metastases from gastrointestinal tumors, even if it can have high false negative rates in patients recently treated with chemotherapy \[[@B55],[@B56]\]. PET scan can be associated to CT scan thus improving the sensitivity up to 97% \[[@B52]\].

Tumor response evaluation is very important in patients with liver tumor that are treated with DEBIRI. The Tumor response--Response Evaluation Criteria in Solid Tumors (RECIST) and WHO has been used since early nineties for tumor response evaluation in clinical trials \[[@B57]\]. The European Association for the Study of the Liver (EASL) and the European Organization for Research and Treatment of cancer has formulated Clinical Practice Guidelines. These guidelines establish that tumor assessment should be done using Modified Tumor response--Response Evaluation Criteria in Solid Tumors (mRECIST) to assess CT or MRI done 4 weeks after treatment. Conventional RECIST criteria are based on tumor shrinkage to measure tumor response. TACE and TARE, however, induce tumor damage and for this reason, there can be tumor response even if the tumor size is the same. The reduction in viable tumor is a better way to estimate tumor response in these cases and for this reason, RECIST criteria was modified \[[@B59]\].

The mRECIST has been recently introduced to overcome the limitations of RECIST and now it is the most used method to assess tumor response in CRC-LM after DEBIRI treatment \[[@B34],[@B35],[@B48],[@B49]\]. This method assesses tumor response as identification of intratumoral necrotic areas and reduction of tumor burden in triphasic CT or MRI \[[@B61]\]. Other modifications of the RECIST include monitoring of vascular invasion, lymph nodes, ascites, pleural effusion and presence of new lesions \[[@B62],[@B63]\].

DEBIRI in combination therapies {#S0008}
-------------------------------

DEBIRI can be associated to systemic therapies to target extrahepatic diseases. The combination of DEBIRI with chemotherapy based on FOLFOX with or without bevacizumab has limited toxicity and higher overall response \[[@B64],[@B65]\]. The combination DEBIRI-FOLFOX or FOLFIRI is also successful for unresectable CRC-LM therapy \[[@B66],[@B67]\]. DEBIRI in association with capecitabine can be used in heavily pretreated patients with positive tolerability and tumor response rates \[[@B68]\]. Also the combination DEBIRI + Cetuximab is safe and active \[[@B36]\].

DEBIRI efficacy {#S0009}
---------------

Cumulative results from single arm studies \[[@B40],[@B69]\] on DEBIRI show that the median OS is 18 months (range 7.3--25) and 33 months when DEBIRI is combined to FOLFOX 6 ([Table 4](#T4){ref-type="table"}). Median PFS is 6.7 months (range 4--11) and 10.8 months when DEBIRI is combined to FOLFOX 6 ([Table 4](#T4){ref-type="table"}). As concerning the tumor response, median overall response rate was 62% (range 10--78%; [Tables 2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}).

###### DEBIRI results in single arm studies: tumor responses.

  Study                        Patients (n)   Responders (CR+PR) mRECIST (%)   PFS (months)   OS (months)   Ref.
  ---------------------------- -------------- -------------------------------- -------------- ------------- ------------
  Aliberti *et al.* (2011)     82             78                               8              25            \[[@B40]\]
  Akinwande *et al.* (2014)    149            40                               7              13            \[[@B69]\]
  Bhutiani *et al.* (2016)     212            53                               NR             NR            \[[@B45]\]
  Eichler *et al.* (2012)      11             22                               5              NR            \[[@B37]\]
  Fiorentini *et al.* (2015)   40             50                               9.8            20.4          \[[@B36]\]
  Huppert *et al.* (2014)      29             72 (EASL)                        5              8             \[[@B70]\]
  Iezzi *et al.* (2015)        20             10                               4              7.3           \[[@B43]\]
  Martin *et al.* (2011)       55             65                               11             19            \[[@B41]\]
  Nayaranan *et al.* (2013)    28             45                               4              13.3          \[[@B71]\]
  Fereydooni *et al.* (2018)   14             69.23                            NR             18.14         \[[@B33]\]
  Pellerin *et al.* (2019)     57             73.2                             10.8           33.1          \[[@B44]\]

CR: Complete response; EASL: European Association for the Study of the Liver; OS: Overall survival; PFS: Progression-free survival; PR: Partial response.

Other studies, according to the method used for tumor response evaluation (RECIST vs mRECIST/EASL), report an objective tumor response ranging between 56.2 and 51.1% \[[@B7]\]. These data further support the beneficial effect of DEBIRI for the treatment of CRC-LM.

Predictive factors {#S0010}
------------------

Survival according to clinical and molecular characteristics of patients can be correlated to CEA level and it could be used as biomolecular prognostic marker in CRC-LM patients treated with DEBIRI \[[@B68]\]. A study monitoring CEA and CA19.9 levels in CRC-LM patients after DEBIRI find an interesting correlation between longer survival and significant CEA level reduction (≥20%), however, the correlation between CEA reduction and tumor response was not statistically significant \[[@B68]\]. If these data are confirmed by further studies with a larger number of patients, DEBIRI could be interrupted in case of CEA levels stability after the first treatment, in order to avoid further sessions that could be not effective.

Another potential biomarker for predicting treatment efficacy and risk of adverse events after DEBIRI is VEGFR1. A recent study monitored the VEGF/R1/R2 levels in colorectal cancer patients after TACE treatment \[[@B33]\]. They showed a decreased VEGFR1 level, but not VEGF and VEGFR2 at 24 h post-treatment. This downregulation of VEGFR1 is associated with the antitumor effect of VEGF and may be correlated with better prognosis \[[@B33]\]. The potential prognostic value of VEGFR1, however, is not confirmed in a conclusive manner, further studies are required to address this issue.

Conclusion {#S0011}
==========

DEBIRI is a promising intra-arterial approach that can be offered alone or in combination with systemic chemotherapy after failure of previous chemotherapy lines. cTACE with lipiodol has positive results for the treatment of HCC \[[@B4]\] and for CRC-LM when used in combination therapies \[[@B72]\]. One recent study on the palliative and neoadjuvant use (with subsequent thermal ablation) of cTACE in unresectable and chemoresistant CRC-LM reports a median OS and PFS of 12.6 and 5.9 months in the palliative setting and 25.8 and 10.8 months for the neoadjuvant use of cTACE \[[@B72]\]. This suggest that cTACE is a more effective treatment option in advanced nonresectable CRC-LM if associated to thermal ablation or other chemotherapeutics (MitomycinC, irinotecan) \[[@B72]\]. TACE can be used in both palliative and therapeutic settings.

DEBIRI is safe and effective for the treatment of unresectable CRC-LM. Irinotecan is a pro-drug and requires activation, occurring in normal liver parenchyma, for this reason lobar infusions should to be preferred. The pH-dependent nature of irinotecan activation and the DEBIRI-induced tumor hypoxia is a unique mechanism of treatment. Periprocedural medications are available to control pain and do not reduce responses to DEBIRI.

Further randomized trials to determinate the ideal patient population, the best timing of treatment, the best techniques for beads delivery are warranted.

Future perspective {#S0012}
==================

Patients with liver metastases from colorectal cancer are often unresectable and/or refractory to systemic therapy, for this reason they are indicated for locoregional therapy. DEBIRI is among the most used locoregional method and is safe and effective for the treatment of unresectable CRC-LM. DEBIRI can also be used as macro-antiangiogenic therapy. This effect can be further enhanced by the combination of DEBIRI with molecular antiangiogenic therapy, such as of bevacizumab, in order to reduce neo-angiogenesis embolization-induced. This could reduce also recurrences while increasing PFS and survival, optimizing the patient's care.

###### Executive summary

-   DEBIRI involves the delivery of DC-Beads inside the hepatic artery of the lobe mainly affected by tumor metastases.

-   The tumor specificity of DEBIRI is given by the presence of a richer vascularity inside the tumor than in the normal liver tissue.

-   DEBIRI efficacy has been confirmed by several studies showing high percentage of tumor response and improved overall survival.

-   There are several types of embolics for the irinotecan delivery. Recent improvements of transarterial chembolization (TACE), including the introduction of new types of embolics (PEG microspheres), have increased tumor response in colorectal cancer liver metastases patients.

-   The adverse events commonly observed after TACE are fever without associated sepsis, pain in the right upper quadrant, pain due to capsular starching associated with postinterventional reaction and swelling, nausea and/or vomiting.

-   Supportive therapy protocol includes a careful therapy with morphine and intra-arterial lidocaine that are administered before the TACE, and antibiotic/antiemetic prophylaxis and intravenous hydration before and after the procedure.

-   The Modified Tumor response--Response Evaluation Criteria in Solid Tumors (mRECIST) has been recently introduced to overcome the limitations of RECITS and now it is the most used method to assess tumor response in colorectal cancer liver metastases after DEBIRI treatment.

-   The combination DEBIRI with FOLFOX, FOLFIRI or Cetuximab is successful for unresectable colorectal cancer liver metastases therapy and safe.
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